Recent Advances in Heart Failure with Preserved Ejection Fraction: 2025 Updates for SCE Cardiology

Heart failure with preserved ejection fraction (HFpEF) represents one of the most challenging and rapidly evolving areas in cardiovascular medicine. As we move through 2025, significant breakthroughs have emerged that are reshaping our understanding and management of this complex syndrome.

Understanding HFpEF: The Growing Epidemic

HFpEF now accounts for approximately 50% of all heart failure cases, affecting over 3 million patients in the UK alone. Unlike heart failure with reduced ejection fraction (HFrEF), HFpEF is characterized by normal left ventricular ejection fraction but evidence of diastolic dysfunction and elevated filling pressures.

Key Recent Advances

1. Novel Pharmacological Therapies

SGLT2 Inhibitors: Following the landmark EMPEROR-Preserved and PRESERVED-HF trials, SGLT2 inhibitors have become first-line therapy for HFpEF. Recent 2025 data from real-world registries demonstrates:

• 21% reduction in cardiovascular mortality

• 27% reduction in heart failure hospitalizations

• Significant improvement in exercise capacity measured by 6-minute walk test

GLP-1 Receptor Agonists: Emerging evidence from the STEP-HFpEF trial shows promising results with semaglutide, particularly in patients with obesity and HFpEF. Recent updates demonstrate:

• Substantial weight loss (mean 7.8 kg at 52 weeks)

• Improved NT-proBNP levels

• Enhanced quality of life scores

ARNI and Mineralocorticoid Receptor Antagonists: The PARAGON-HF trial continues to inform practice, with ARNIs showing particular benefit in patients with LVEF in the mid-range (45-57%).

2. Diagnostic Advances

Artificial Intelligence in Echocardiography: Machine learning algorithms now assist in detecting early diastolic dysfunction, improving diagnostic accuracy by 34% in recent validation studies.

Cardiac MRI Biomarkers: T1 and T2 mapping techniques have enhanced our ability to identify myocardial fibrosis, a key pathological feature in HFpEF.

3. Emerging Treatment Strategies

Precision Medicine Approaches: Recent work has identified distinct HFpEF phenotypes:

• Vascular phenotype (elderly, hypertension)

• Metabolic phenotype (obesity, diabetes)

• Atrial phenotype (atrial fibrillation dominant)

• Mixed cardiomyopathy phenotype

This phenotyping approach allows for targeted therapy selection.

Device Therapy: New data on atrial shunt devices shows promise for select patients with elevated left-sided filling pressures.

Implications for SCE Cardiology Exam

Candidates must be familiar with:

• Updated diagnostic criteria incorporating echocardiographic parameters

• Current guideline-directed medical therapy (GDMT) algorithm

• Evidence base for SGLT2 inhibitors as first-line treatment

• Phenotype-specific management approaches

Clinical Pearls for Practice

1. Diagnosis requires: Signs/symptoms of heart failure + evidence of diastolic dysfunction + elevated natriuretic peptides

2. First-line treatment: SGLT2 inhibitors regardless of diabetes status

3. Key investigations: Echocardiography, ECG, chest X-ray, NT-proBNP, and increasingly cardiac MRI

4. Comorbidity management: Aggressive treatment of hypertension, atrial fibrillation, and obesity

Conclusion

The management of HFpEF has transformed dramatically in recent years. With SGLT2 inhibitors now established as cornerstone therapy and multiple new agents in development, outcomes for patients with HFpEF continue to improve. For SCE Cardiology candidates, understanding these recent advances is essential for both exam success and future clinical practice.

Stay updated with the latest ESC guidelines and be prepared to apply this evidence-based knowledge in clinical scenarios.